The FDA has approved pimicotinib (Pimjetmi, EMD Serono) for treating symptomatic tenosynovial giant cell tumors where surgery would worsen functional limitations, marking another win for Merck KGaA's rare tumor strategy.
Revolution Medicines' RAS inhibitor Rasonque is tracking as the best cancer drug launch in history by early sales metrics, with Wall Street analysts resetting projections upward. Company executives cautioned it is too early to draw firm conclusions.
Researchers at Fox Chase Cancer Center discovered that blocking the anoctamin 6 (ANO6) protein can slow pancreatic tumor growth and reduce immune suppression in preclinical trials. The study reveals that cancer-associated fibroblasts transfer membrane lipids to cancer cells through ANO6-dependent trogocytosis, fueling tumor progression.
Researchers at MD Anderson Cancer Center discovered that the METTL13 enzyme modifies translation machinery to selectively enhance production of cancer-driving proteins like KRAS, offering a potential new therapeutic target upstream of existing KRAS-targeted drugs that face resistance issues.
A study led by Adelaide University and SAHMRI provides the first direct evidence that asciminib, a targeted therapy for chronic myeloid leukemia, can rapidly and consistently suppress the cancer-driving protein within one week, offering a more effective and better-tolerated treatment option for CML patients.
A Mayo Clinic study published in the Journal of Neuro-Oncology demonstrates that analyzing DNA in cerebrospinal fluid can provide diagnostic information for brain tumors when MRI imaging is unclear or tissue biopsy is difficult or unsafe to obtain.
Genmab's experimental antibody-drug conjugate Rina-S reduced the risk of death by 57% compared to chemotherapy in patients with advanced ovarian cancer, according to phase 3 trial results presented at ESMO. The Danish drugmaker's shares surged over 12% on the news.
Roche's next-generation KRAS G12C inhibitor divarasib reduced the risk of death by 44% compared to current treatments in previously treated mutant non-small cell lung cancer patients, with median overall survival reaching nearly 6 months longer than competitors.
AstraZeneca's experimental antibody-drug conjugate sone-ve doubled survival time in patients with advanced stomach cancer who had received at least two prior treatments, exceeding analyst expectations in late-stage trial data.
Results from France's early-access program demonstrate that PSMA-targeted radiopharmaceutical therapy Lu-PSMA-617 is safe and effective for patients with metastatic castration-resistant prostate cancer in routine clinical practice, confirming findings from controlled trials.
An international research team led by RCSI University of Medicine and Health Sciences and The Institute of Cancer Research, London has identified potential new treatment approaches for microsatellite-stable colorectal cancer, the most common type in Ireland. The study provides a roadmap for repurposing existing drugs to treat this cancer subtype.
A new analysis of a phase 3 clinical trial presented at ESMO 2026 found that daraxonrasib, a recently approved targeted therapy, improved survival compared with standard chemotherapy across multiple patient groups with advanced pancreatic cancer. The drug represents the biggest advance in decades against the notoriously hard-to-treat disease.
Researchers have developed RPT04402, a molecular glue that stabilizes protein phosphatase 2A (PP2A), a key regulator of cell signaling pathways frequently disrupted in tumors. The compound shows promise in inhibiting non-small cell lung cancer and uterine cancer development.
The FDA approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a chemotherapy-free maintenance treatment for adults with HER2-positive metastatic breast cancer. The approval was supported by data showing more than 50% improvement in median progression-free survival.
Taiho Oncology and Cullinan Therapeutics announced their next-generation EGFR inhibitor zipalertinib significantly improved progression-free survival in a registrational phase 3 trial for first-line treatment of advanced non-small cell lung cancer. The results position the drug as a competitor to multiple approved medicines in the EGFR-mutated lung cancer market.
A Nature Cell Biology study identifies a novel therapeutic vulnerability in acute myeloid leukemia with FLT3 mutations, showing that FLT3 inhibitors trigger ferroptosis in cancer cells. The findings complement ongoing advances in FLT3-ITD+ AML treatment, including improved minimal residual disease testing and updated clinical practice guidelines.
UK pharmaceutical giant GSK has entered an agreement to acquire U.S.-based cancer drugmaker Nuvalent for $10.6 billion, adding targeted cancer therapies to its portfolio in one of the year's largest biopharma acquisitions.